The presentation of the findings about the capabilities of IS26 arising from the recent body of work conducted in my laboratory in the recent review “The IS6 family, a clinically important group of insertion sequences including IS26” by Varani, He, Siguier, Ross and Chandler [5] raises concerns with respect to inaccuracies and misrepresentation. Indeed, Varani and co-authors claim that there is “an absence of formal proof” for the existence of the targeted conservative mechanism. As I believe that our in depth experimental approach to the reactions that occur in vivo has produced a level of information that would normally be considered to amount to formal proof, I recommend that the original references should be read before their view is accepted.

We have explored aspects of the requirements of the targeted conservative reaction in more detail [3, 6] and the speculative mechanism for the targeted conservative route presented by Varani et al. in Fig. 11 is of particular concern because it is not consistent with those experimental findings. In fact, the 2017 study [6] that established that only one end of each participating IS26 is needed for the targeted conservative reaction to occur was not cited. A model that is consistent with the currently available data can be found in Fig. 5 in [3]. However, further work is still needed.

In addition, we have shown experimentally that the targeted conservative mechanism can generate the IS26-bounded pseudo-compound transposons and the overlapping pseudo-compound transposon configurations found in many multiply antibiotic resistant Gram-negative pathogens [1, 7]. This route involves a non-replicating circular intermediate containing a single IS26 that was named a translocatable unit (TU). However, Varani et al. also question the existence of TU, even though they clearly can be formed de novo at very low frequency via the copy-in mechanism in adjacent deletion mode, and this is the first step in the likely route to initial resistance gene recruitment. IS26-mediated insertion of such TU by either mechanism then generates a pseudo-compound transposon. TU can also arise readily by homologous recombination between any directly-oriented pair of IS26s such as those flanking pseudo-compound transposons. Hence, pseudo-compound transposons can change their location via a TU formed by homologous recombination followed by IS26 action [8]. This is in clear contrast to the claim in the review that pseudo-compound transposon movement can only occur via cointegrate formation between two replicons followed by resolution via homologous recombination.

In addition, we have identified the group of IS that share most similarity to IS26 in their transposases and terminal inverted repeats allowing the inference that they are most likely to share the dual mechanistic capabilities of IS26. We refer to the members of the group of six clades most closely related to IS26 (see Figs. 1 and 3 in [9]) as the IS26 family [9]. In contrast, Varani et al. prefer a much larger family that they call the IS6 family. However, then they have claimed, via use of “IS6 family members” or equivalent when describing the properties of IS26-based pseudo-compound transposons and our experimental data, that our findings are applicable to all members of the IS6 family, as they define it. However, our data were obtained only with IS26 or with a few related IS (IS257/IS431, IS1216, IS1006, IS1008 and an IS1006/1008 hybrid) that are members of the IS26 family as we define it [9]. We have been unable to find any experimental evidence for an activity of any member of the additional very distantly related groups that are included in their IS6 family, and none was cited. Hence, to the best of our knowledge, the claim that these more distantly related IS have the same mechanistic capabilities as IS26 and relatives, which is implicit in their assignment of these IS to the same family, is not supported by any evidence.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Disclaimer:

This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

Click here for Source link (https://www.biomedcentral.com/)